Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
SVB Leerink Presentation Feb 24, 2021
Corporate Deck February 2021
Corporate Deck January 2021
JPM Presentation Jan 14, 2021
Investor Deck December 2020
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Press Releases
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
press release
July 2, 2021
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and…
Read moreObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
press release
June 30, 2021
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for…
Read moreObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
press release
June 24, 2021
– Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2021
May 28, 2021
ObsEva Annual General Meeting 2020
June 9, 2020
Upcoming Events
Sorry, there are no events available yes.
Stock Information
Latest Press Release
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
